2025-11-24 - Analysis Report
Okay, let's analyze Eli Lilly (LLY) based on the provided data.

**1) Return Rate Comparison:**

*   **Company Overview:** Eli Lilly and Co is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.
*   **LLY Cumulative Return:** 303.45%
*   **VOO (S&P 500) Cumulative Return:** 94.64%
*   **Divergence:** 208.8 (Relative Divergence: 85.9)

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the analyzed period. The current divergence is substantial, and the relative divergence of 85.9 suggests the outperformance is near the higher end of its historical range compared to the S&P 500. This implies that, relatively speaking, LLY's outperformance is currently strong.

**Alpha, Beta Analysis:**

| Year       | CAGR  | MDD   | Alpha  | Beta | Cap(B) |
|------------|-------|-------|--------|------|--------|
| 2015-2017  | 11.0% | 76.1% | -17.0% | -0.0 | 75.7   |
| 2016-2018  | 39.0% | 68.9% | 24.0%  | 0.1  | 103.7  |
| 2017-2019  | 41.0% | 68.9% | 19.0%  | 0.4  | 117.8  |
| 2018-2020  | 34.0% | 79.8% | 10.0%  | 0.3  | 151.4  |
| 2019-2021  | 53.0% | 79.8% | 7.0%   | 0.5  | 247.6  |
| 2020-2022  | 64.0% | 79.8% | 65.0%  | 0.4  | 328.0  |
| 2021-2023  | 125.0% | 78.9% | 124.0% | 0.2  | 522.6  |
| 2022-2024  | 134.0% | 81.2% | 113.0% | 0.2  | 692.1  |
| 2023-2025  | 195.0% | 83.5% | 136.0% | 0.2  | 950.0  |

*   **CAGR:** Shows strong annualized growth, accelerating in recent years.
*   **MDD (Maximum Drawdown):** Indicates a significant level of risk, with drawdowns consistently high. This suggests potential volatility.
*   **Alpha:** Demonstrates LLY's ability to generate returns above what would be expected based on its Beta (market sensitivity). Alpha has been exceptional in recent periods.
*   **Beta:** Relatively low Beta values (close to 0.2 ~0.5) suggest that LLY's price is not highly correlated with the broader market, indicating that it's relatively less volatile than the market, and potentially driven by company-specific factors.
*   **Cap(B):** Market capitalization has grown substantially, reflecting the company's strong performance.

**2) Recent Stock Price Fluctuations:**

*   **Close:** 1059.70
*   **Last-market change:** 1.57% increase from the previous close.
*   **5-day SMA:** 1040.87
*   **20-day SMA:** 951.41
*   **60-day SMA:** 837.55

**Analysis:** The current price is above all three moving averages, indicating an uptrend. The 5-day SMA is above the 20-day SMA, and the 20-day SMA is above the 60-day SMA, further confirming this trend. The recent price increase suggests continued positive momentum.

**3) Indicator Analysis:**

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment) - Suggests that the stock is moderately risky.
*   **RSI:** 81.99 -  This is in overbought territory (above 70), suggesting the stock may be due for a pullback.
*   **PPO:** 0.53 -  Positive PPO indicates a positive trend.
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00)" -  This suggests a strong buy signal from the hybrid model. The MRI of 0.90 assigned to the signal itself is quite high, suggesting the *model* views the opportunity as relatively safe.
*   **Recent Relative Divergence Change:** 6.0 (+) "단기상승" (short-term increase) - The divergence between LLY and VOO has increased recently, meaning LLY is outperforming even in the short term.
*   **Expected Return:** 46.5% - A very high expected return compared to the S&P 500, assuming a long-term investment horizon.

**Analysis:** While the RSI indicates a potential overbought condition, the strong hybrid signal and high expected return suggest continued positive sentiment. The recent increase in relative divergence reinforces the short-term bullish outlook.

**4) Recent News & Significant Events:**

*   **Eli Lilly Stock Value Tops $1 Trillion:** This milestone likely contributes to positive investor sentiment and increased buying pressure.
*   **Will Eli Lilly Stock (LLY) Split? Rumors Are Swirling:** A stock split could make the stock more accessible to smaller investors, potentially driving the price higher.
*   **Jim Cramer Comments On Eli Lilly (LLY)’s Shares After Pfizer CEO’s Remarks:** This suggests ongoing market interest and discussion surrounding LLY's performance and competitive landscape.
*   **Stock Quote & Chart | Eli Lilly and Company:** Normal news
*   **LLY - Lilly(Eli) & Co Stock Price and Quote:** Normal news
*   **Eli Lilly Tops $1 Trillion, Joins Tech Titans In Exclusive Club:** Reinforces the positive momentum and achievement of a significant market capitalization.

**Analysis:** The news is overwhelmingly positive, highlighting LLY's strong performance, market capitalization milestone, and potential stock split, which could further boost the stock price.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.77)
*   **Target Price:** Avg: 1012.19 / High: 1500.00 / Low: 770.00

**Analysis:** The analyst consensus is "Buy", indicating positive expectations for the stock. While the average target price (1012.19) is below the current price (1059.70), the high target price (1500.00) suggests some analysts see significant upside potential. The recent rating changes could provide further insight, but the details are missing.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-10-30 | 6.22  | 17.60 B$   |
| 2025-08-07 | 6.3   | 15.56 B$   |
| 2025-05-01 | 3.07  | 12.73 B$   |
| 2024-10-30 | 1.08  | 11.44 B$   |
| 2025-10-30 | 1.08  | 11.44 B$   |

**Analysis:**  Earnings per share (EPS) and revenue have shown strong growth in recent quarters. The increase in both EPS and revenue suggests that the company is performing well financially. It is important to note the 2025-10-30 data appears twice, which might indicate an error in the data set.

**6) Financial Information:**

Revenue and Profitability:

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $17.60B   | 82.91%        |
| 2025-06-30   | $15.56B   | 84.27%        |
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |

Capital and Profitability:

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $23.79B   | 23.46%  |
| 2025-06-30   | $18.27B   | 30.98%  |
| 2025-03-31   | $15.76B   | 17.50%  |
| 2024-12-31   | $14.19B   | 31.07%  |
| 2024-09-30   | $14.24B   | 6.81%   |

**Analysis:** Revenue is consistently growing, and profit margins are extremely high, indicating excellent operational efficiency.  Equity has also increased significantly, and return on equity (ROE) is very strong, demonstrating the company's ability to generate profits from shareholder investments.

**7) Comprehensive Analysis:**

Eli Lilly is exhibiting strong performance across multiple dimensions:

*   **Market Outperformance:** Significantly outperforming the S&P 500.
*   **Financial Strength:** Strong revenue growth, high profit margins, and excellent ROE.
*   **Positive Momentum:**  Uptrending stock price, recent positive divergence change, and strong recent news headlines.
*   **Analyst Confidence:**  Positive analyst consensus with a "Buy" rating.
*   **Company Fundamentals:** The consistent and robust increase in revenue and profit signifies that LLY's core business activities are thriving.
*   **High Growth Potential:**  The substantial increase in market capitalization and analysts' high target price suggests that the company has plenty of upside potential.

**Concerns:**

*   **Overbought Condition:** The high RSI suggests a potential pullback.
*   **High MDD:** The high maximum drawdown values indicate potential volatility and the need for risk management.
*   **Valuation:** While the expected return is high, it's important to consider whether the current valuation fully reflects future growth prospects.

**Overall:**

Based on the provided data, Eli Lilly appears to be a strong investment opportunity with significant growth potential. However, it's crucial to be aware of the potential for a short-term pullback due to overbought conditions and the inherent volatility of the stock. Investors should carefully consider their risk tolerance and conduct further due diligence before making any investment decisions. The discrepancies in the earnings data should also be verified.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.